Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body

Ahmad Samir Alfaar 1,2 · Anas M. Saad 3 · Mahmoud Tawfik KhalafAllah 4,5 · Omneya Ezzat Elsherif 6 · Moataz Hamed Osman 7 · Olaf Strauß 1

Received: 13 February 2020 / Revised: 9 August 2020 / Accepted: 12 August 2020 / Published online: 1 September 2020
© The Author(s) 2020

Abstract

Purpose The eye and its adnexal structures can give rise to first or consecutive primary malignancies or to encounter metastasis. Our aim was to define the characteristics of the second primary neoplasms affecting the eye and its adnexa and find the risk modifying factors for them after malignancies elsewhere in the body.

Methods We have queried the Surveillance, Epidemiology and End-Results “SEER”-9 program of the National Cancer Institute for the malignancies of the eye and its adnexa that occurred between 1973 and 2015. The malignancies were ordered chronologically according to their incidence: first or second primary malignancies. The tumors were classified according to ICD-O-3 classification. Standardized incidence ratios (SIR) and survival probabilities were calculated for subgroups.

Results Among 3,578,950 cancer patients, 1203 experienced a second malignancies of the eye and its adnexa. The first malignancy was diagnosed between 50 and 69 years of age in 58.94% of them. The eyelid showed 280 events, while 50 in lacrimal gland, 181 in the orbit, 21 in the overlapping lesions, 15 in optic nerve, 148 in the conjunctiva, 9 in the cornea, 6 in the Retina, 379 in the choroid, and 93 in the ciliary body. The SIR of a second malignancy after a prior non-Hodgkin lymphoma was 2.42, and in case of previous skin carcinomas it was 3.02, melanoma of skin, and 2.13 and 1.58 in oral cavity/pharynx malignancies. The second ocular and adnexal neoplasms increased steadily over the 5-year periods on contrary to first primary neoplasms. The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms. On the other side, second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere.

Conclusions The epidemiological differences between first and second ocular and adnexal primaries suggest different underlying mechanisms. Careful ocular examination should be integrated in the long-term follow-up plan of cancer patients. Special attention should be given to patients with non-Hodgkin’s lymphoma and melanoma as first primary.

Ahmad Samir Alfaar and Anas M. Saad contributed equally to this work.

The data in this article were presented as an abstract and oral presentation in the German Ophthalmological Society meeting DOG 2019, Berlin, Germany

Further data analysis will be made available on the following page: [doi:10.5281/zenodo.3999062]

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00417-020-04896-1) contains supplementary material, which is available to authorized users.
Introduction

The eye and its ocular adnexa (EOA) are affected by a broad spectrum of malignant tumors. Enhanced by the more prolonged survival of cancer cured patients and the better diagnostic techniques, a rising incidence of second ocular and adnexal primary cancers have been detected. However, the paucity of large case series braked establishing distinct epidemiological patterns [1].

Second primary malignant tumors (SPMTs) are defined as new primary malignant tumors that are encountered after another primary one. Different factors are involved, yet, without an established pattern. Genetic predisposition, environmental factors, and various treatment options are correlated with the second primary malignancies. SPMTs are challenging in many aspects. For diagnosis, symptoms can be overlooked in the context of fatigability attributed to the primary tumor and/or its therapy. For therapy, planning another therapeutic course, like radiotherapy, after a prior one can have various drawbacks, including induction of another malignancy [2–5].

Virtually every malignancy has the potential to send secondaries to the eye and its adnexa. The most common primary sites to metastasize this region are the breast and the lung. In most situations, metastatic tumors at the EOA present first and incite the search for a primary. Breast is an exception, with nearly 90% of its secondaries are discovered after a primary malignancy therapy [6–11].

On the contrary, SPMTs in the ocular and its adnexal region do not have an established epidemiological pattern. The EOA–SPMTs are rarely reported as a distinct entity with calculated risk as other regions. Instead, they are usually categorized with other sites as “others.” Therefore, this study is conducted [2, 5, 12].

Methods

Study design and data source

This study represents a retrospective cohort study of patients registered in Surveillance, Epidemiology and End-Results “SEER9” registry, which cover about 9.4% of the general US population between 1973 and 2015 [13].

Study population

We examined the records of patients diagnosed with a second primary cancer in the EOA after being diagnosed with at least one primary prior cancer elsewhere in the body. We allowed at least 2 months period between the diagnosis of the first and the second cancers. We defined cancers of interest as malignancies occurring in the eyelid, conjunctiva, cornea, retina, choroid, ciliary body, lacrimal glands, overlapping lesions of the eye and adnexa, and optic nerve. For this selection, we used the ICD-O-3 topographic classification with the codes: C44.1, C69.0-9, and C72.3. SEER data are anonymized and considered non-human subject research. Thus, it is IRB approval and HIPAA is exempted.

Within all included patients, we have revised the demographic characteristics besides the site of the first and further malignancies, histological subtype of the malignancies using
Table 1  Baseline characteristics of patients at their first malignancy (n = 1203)

| Characteristics | Number | Column N % |
|----------------|--------|------------|
| **Sex**        |        |            |
| Female         | 543    | 45.14%     |
| Male           | 660    | 54.86%     |
| **Age group**  |        |            |
| 0–19 years     | 7      | 0.58%      |
| 20–39 years    | 55     | 4.57%      |
| 40–59 years    | 333    | 27.68%     |
| 50–69 years    | 709    | 58.94%     |
| 70 years–older | 99     | 8.23%      |
| **Race (White, Black, other)** |    |            |
| White          | 1124   | 93.43%     |
| Black          | 34     | 2.83%      |
| Othera         | 45     | 3.74%      |
| **Marital status at diagnosis** |       |            |
| Divorced       | 59     | 4.90%      |
| Married (including common law) | 806   | 67.00%     |
| Separated      | 11     | 0.91%      |
| Single (never married) | 110  | 9.14%      |
| Unknown        | 87     | 7.23%      |
| Widowed        | 130    | 10.81%     |
| **State**      |        |            |
| California     | 232    | 19.29%     |
| Connecticut    | 187    | 15.54%     |
| Georgia        | 71     | 5.90%      |
| Hawaii         | 42     | 3.49%      |
| Iowa           | 169    | 14.05%     |
| Michigan       | 185    | 15.38%     |
| New Mexico     | 54     | 4.49%      |
| Utah           | 79     | 6.57%      |
| Washington     | 184    | 15.30%     |
| **AYA site/WHO 2008** |     |            |
| 1.2 Acute myeloid leukemia | 3  | 0.25%      |
| 1.3 Chronic myeloid leukemia | 4  | 0.33%      |
| 1.4 Other and unspecified leukemia | 19 | 1.58%      |
| 2.1 Non-Hodgkin lymphoma | 83 | 6.90%      |
| 2.2 Hodgkin lymphoma | 4  | 0.33%      |
| 3.1.1 Specified low-grade astrocytic tumors | 1  | 0.08%      |
| 3.1.3 Astrocytoma, NOS | 2  | 0.17%      |
| 3.2 Other glioma | 2  | 0.17%      |
| 4.1 Osteosarcoma | 1  | 0.08%      |
| 4.2 Chondrosarcoma | 3  | 0.25%      |
| 5.1 Fibromatous neoplasms | 1  | 0.08%      |
| 5.3.1.1 Specified (excluding Kaposi sarcoma) | 8  | 0.67%      |
| 5.3.1.2 Kaposi sarcoma | 2  | 0.17%      |
| 6.1 Germ cell and trophoblastic neoplasms of gonads | 9  | 0.75%      |
| 7.1 Melanoma | 114 | 9.48%      |
| 7.2 Skin carcinomas | 6  | 0.50%      |
| 8.1 Thyroid carcinoma | 23 | 1.91%      |
| 8.2.1 Nasopharyngeal carcinoma | 1 | 0.08%      |
| 8.2.2 Other sites in lip, oral cavity, and pharynx | 37 | 3.08%      |
| 8.2.3 Nasal cav, mid ear, sinus, larynx, ill-def head/neck | 19 | 1.58%      |
| 8.3 Carcinoma of trachea, bronchus, and lung | 39 | 3.24%      |
| 8.4 Carcinoma of breast | 206 | 17.12%     |
| 8.5.1 Carcinoma of kidney | 17 | 1.41%      |
| 8.5.2 Carcinoma of bladder | 65 | 5.40%      |
adolescent and young adults (AYA) recode variable, treatment modalities for the first malignancy, vital status at the end of follow up (end of 2015), and the survival period.

Outcomes and statistical analyses

We have used Multiple Primary-Standard Incidence Ratio (MP-SIR) session in SEER*Stat version 8.3.5 [13] to calculate O/E ratios, which represent the number of actually diagnosed cases of the malignancies of the EA following a prior primary malignancy, divided by the number of expected cases of similar locations in a demographically similar population. To calculate these rates, patients with unknown race were grouped with whites. We calculated O/E ratios for each site of EA cancers, and according to different demographic and tumor-related characteristics.

We performed Kaplan–Meier test to calculate the overall survival of patients who developed second primary EA malignancies. We used the log-rank test to compare the overall survival of these patients with patients who have primary EA malignancies without prior malignancies, and with the overall survival of patients who developed second primary malignancies in sites elsewhere. We used IBM SPSS 24 for survival analyses. All tests were two-sided, and a $p$ value that is less than 0.05 was considered statistically significant.

Results

Baseline characteristics

We reviewed a total of 3,578,950 cancer patients' records, of which 1222 primary malignancies of the EA in 1203 patients after a previous malignancy elsewhere. From those patients, 93.4% were whites, 67% were married, and about 58.94% of them were 50–69 years old when they were diagnosed with their first malignancy. Male-to-female ratio was 1.22, where males represented 54.9% of the patients. The median time to develop a second primary ocular and ocular adnexal malignancy was 9.7 years following the first cancer diagnosis. The most common sites of the first malignancy were prostate and genitourinary tract (24.5%), and breast (17.12%) (Table 1). The age-adjusted rate showed a steady increase over 5-year periods since 1976 (Fig. 1).

Risk of second primary eye or ocular adnexal malignancy following a cancer diagnosis

We found the overall risk of developing a second primary EOA malignancy to increase significantly following a cancer diagnosis (O/E = 1.16, 95%CI (1.09–1.22)). This increase was significant in both males and females (O/E = 1.14, 95%CI (1.06–1.23), and O/E = 1.18, 95%CI (1.08–1.28), respectively). A prior non-Hodgkin lymphoma, or skin melanoma, were associated with significant increases in the risk; O/E = 2.42, 95%CI (1.93–2.99), and O/E = 2.13, 95%CI (1.76–2.55), respectively. On the other hand, a prior colorectal, breast, prostate, respiratory, or urinary bladder cancers, were not associated with significant overall changes in risk.

We further divided the second ocular and adnexal malignancies according to their specific sites. The risks of 2nd primary in the eyelid, ciliary body, and optic nerve malignancies were significantly higher; O/E = 1.35, 95%CI (1.20–1.52), O/E = 1.43, 95%CI (1.16–1.76), and O/E = 3.82, 95%CI (2.14–6.30), respectively. Details on risks of each site are described in Tables 2 and 3.
On the other hand, 454,005 patients developed second non-EOA primary malignancy after another non-EOA malignancies with a smaller but significant increase in risk; O/E = 1.07, 95%CI (1.07–1.08), but the excess risk was 11.94 per 10,000. Table 1 shows the baseline characteristics of patients who developed an SPMT in the EOA.

To study the impact of having a prior malignancy on the survival of the EOA malignancies, we compared the overall survival of the patients divided according the milestone of where they developed EOA malignancy versus the patients who did develop non-EOA malignancy. Patients with single EOA malignancies with no other associations (n = 9376 patients) showed lower survival until 10 years after the diagnosis then showed a better survival after 25 years. On the other side, second EOA malignancies showed steady higher overall survival until 25 years after the diagnosis (median 201 months, 95%CI (188.14–213.86)).

Patients who developed first and second malignancies both not involving EOA (n = 396,677 patients) showed the worst
### Table 2  Risk of developing second primary malignancy in conjunctiva, cornea, retina, choroid, and ciliary body

|                        | C69.0-Conjunctiva | C69.1-Cornea | C69.2-Retina | C69.3-Choroid | C69.4-Ciliary body | C69.9-Eye, NOS |
|------------------------|-------------------|--------------|--------------|---------------|-------------------|---------------|
|                        | NE | O/E | NE | O/E | NE | O/E | NE | O/E | NE | O/E | NE | O/E |
| **Total**              | 148| 1.05| 9  | 0.80| 6  | 0.79| 379| 1.04| 93 | 1.43#| 49 | 0.98 |
| **Sex**                |     |     |    |     |     |     |     |     |     |     |     |     |
| Female                 | 50 | 1.04| 1  | 0.50| 5  | 1.36| 173| 1.08| 41 | 1.39 | 19 | 0.85 |
| Male                   | 98 | 1.05| 8  | 0.86| 1  | 0.25| 206| 1.02| 52 | 1.47#| 30 | 1.09 |
| **Age at diagnosis of first malignancy** |     |     |    |     |     |     |     |     |     |     |     |     |
| 0–19 years             | 0  | 0.00| 0  | 0.00| 1  | 2.78| 0  | 0.00| 1  | 6.77 | 0  | 0.00 |
| 20–39 years            | 6  | 1.37| 0  | 0.00| 0  | 0.00| 18 | 1.24| 7  | 3.00#| 1  | 0.78 |
| 40–59 years            | 38 | 1.13| 0  | 0.00| 1  | 0.47| 125| 1.09| 28 | 1.50 | 15 | 1.25 |
| 60–79 years            | 95 | 1.07| 6  | 0.83| 4  | 0.89| 216| 1.02| 50 | 1.27 | 28 | 0.91 |
| 80+ years              | 9  | 0.64| 3  | 1.36| 0  | 0.00| 20 | 0.92| 7  | 1.68 | 5  | 0.86 |
| **Site recode ICD-O-3/WHO 2008 of first malignancy** |     |     |    |     |     |     |     |     |     |     |     |     |
| All solid tumors       | 125| 0.95| 7  | 0.66| 6  | 0.86| 358| 1.06| 84 | 1.40#| 42 | 0.91 |
| Oral cavity and pharynx| 8  | 2.30| 0  | 0.00| 0  | 0.00| 8  | 0.88| 2  | 1.17 | 2  | 1.63 |
| Digestive system       | 17 | 0.81| 2  | 1.04| 0  | 0.00| 48 | 0.96| 15 | 1.57 | 8  | 1.02 |
| Respiratory system     | 10 | 1.37| 1  | 1.62| 0  | 0.00| 11 | 0.58| 7  | 1.93 | 4  | 1.52 |
| Bones and joints       | 0  | 0.00| 0  | 0.00| 1  | 79.34#| 0  | 0.00| 0  | 0.00 | 0  | 0.00 |
| Soft tissue including heart | 0  | 0.00| 0  | 0.00| 0  | 0.00| 2  | 1.02| 1  | 2.89 | 0  | 0.00 |
| Skin excluding basal and squamous | 12 | 1.58| 2  | 3.79| 0  | 0.00| 36 | 1.64#| 4  | 1.12 | 1  | 0.40 |
| Melanoma of the skin   | 11 | 1.56| 1  | 2.06| 0  | 0.00| 35 | 1.71#| 4  | 1.19 | 1  | 0.43 |
| Other non-epithelial skin | 1  | 1.80| 1  | 23.66| 0  | 0.00| 1  | 0.71| 0  | 0.00 | 0  | 0.00 |
| Breast                 | 16 | 0.77| 0  | 0.00| 2  | 1.33| 86 | 1.23| 15 | 1.20 | 7  | 0.74 |
| Female genital system  | 3  | 0.36| 0  | 0.00| 2  | 3.05| 22 | 0.77| 8  | 1.48 | 3  | 0.75 |
| Male genital system    | 46 | 1.01| 3  | 0.67| 1  | 0.57| 108| 1.14| 19 | 1.19 | 15 | 1.15 |
| Prostate               | 44 | 0.99| 3  | 0.68| 1  | 0.58| 103| 1.13| 19 | 1.23 | 15 | 1.18 |
| Urinary system         | 9  | 0.65| 0  | 0.00| 0  | 0.00| 26 | 0.80| 10 | 1.69 | 2  | 0.44 |
| Brain and other nervous system | 0  | 0.00| 0  | 0.00| 0  | 0.00| 0  | 0.00| 2  | 8.04 | 0  | 0.00 |
| Endocrine system       | 4  | 1.58| 0  | 0.00| 0  | 0.00| 12 | 1.50| 1  | 0.76 | 0  | 0.00 |
| Thyroid                | 4  | 1.65| 0  | 0.00| 0  | 0.00| 11 | 1.43| 1  | 0.79 | 0  | 0.00 |
| All lymphatic and hematopoietic diseases | 19 | 2.17#| 1  | 1.54| 0  | 0.00| 19 | 0.80| 9  | 2.15 | 5  | 1.64 |
| Lymphoma               | 15 | 2.84#| 1  | 2.74| 0  | 0.00| 8  | 0.55| 8  | 3.16#| 4  | 2.22 |
| Hodgkin lymphoma       | 0  | 0.00| 0  | 0.00| 0  | 0.00| 0  | 0.00| 0  | 0.00 | 1  | 4.64 |
| Non-Hodgkin lymphoma   | 15 | 3.26#| 1  | 3.06| 0  | 0.00| 8  | 0.64| 8  | 3.69#| 3  | 1.89 |
| Myeloma                | 0  | 0.00| 0  | 0.00| 0  | 0.00| 2  | 0.90| 0  | 0.00 | 0  | 0.00 |
| Leukemia               | 4  | 1.53| 0  | 0.00| 0  | 0.00| 9  | 1.32| 1  | 0.81 | 1  | 1.07 |
survival 10 years after diagnosis (median 162 months, 95%CI [151.2–172.8]) (Fig. 2).

**Discussion**

Innocent ocular symptoms, including change of refractive error, dryness, or allergy, may masquerade a hidden malignancy. Moreover, such lesions can be the first sign of metastasis [14, 15]. Secondary malignancy is terminology-wise mistaken with second-primary tumors [16]. Secondary tumors may refer to metastatic tumors or relapsing tumors of ocular or adnexal origin. Our paper focuses on the risk of developing a second malignancy in the eye or its adnexa after the incidence of a previous primary malignancy elsewhere in the body.

Improvements in the early detection and the treatment protocols have led to more cancer survivors, hence an increase in the number of patients developing subsequent cancers. We found that the overall risk of developing a second primary EOA malignancy increases significantly following a cancer diagnosis compared with the incidence of the primary EOA malignancies in general population. This is consistent with many other studies that documented the incidence of second malignancies among cancer survivors. Understanding the pattern of second malignancies is essential for planning the follow-up and screening protocols after the first cancer diagnosis.

Curtis et al. found that cancer survivors had a 14% higher risk to develop a new malignancy compared with that expected in the general population. They showed cumulative incidence of 5.0%, 8.4%, 10.8%, and 13.7% at 5, 10, 15, and 25 years, respectively [17]. This risk may be a result of the lifestyle, genetic predisposition, environmental exposures, and/or the effects of cancer therapy [18].

Many studies evaluated the risk of a second malignancy in specific sites. Between 1973 and 2011, Lains et al. followed patients diagnosed with uveal melanoma as their first malignancy. They found an 11% excess risk of a second malignancy, mainly due to a significantly increased risk of skin melanomas and kidney tumors. Radiotherapy showed no effect on this risk [18]. Abramson et al. reported 28 third tumors developed in 211-s tumor survivors of retinoblastoma patients within a median time of 5.8 years [19].

The pattern of second primary malignancies in our results contradicts that in metastatic tumors where the breast followed by the lung were the most common primary sites for metastasis either for the ocular adnexa or the eye [11, 20, 21].

In our study, SIR was statistically significant in females and those between 20 and 39, and 40–59 years. Among the sites of primary cancers, the skin melanoma came first, followed by non-Hodgkin’s lymphoma (NHL). This is in agreement with different studies that
### Table 3  Risk of developing second primary malignancy in eyelid, lacrimal gland, orbit, optic nerve, or overlapping lesions

|                     | C44.1-Eyelid | C69.5-Lacrimal gland | C69.6-Orbit, NOS | C69.8-Overlapping lesion of eye and adnexa | C72.3-Optic nerve |
|---------------------|--------------|----------------------|-----------------|-------------------------------------------|------------------|
|                     | NE1 | O/E | NE | O/E | NE | O/E | NE | O/E | NE | O/E | NE | O/E |
| Total               | 280 | 1.35# | 50 | 1.21 | 181 | 1.15 | 21 | 1.37 | 15 | 3.82# |
| **Sex**             |     |      |    |      |     |      |    |      |     |      |     |      |
| Female              | 134 | 1.37# | 24 | 1.11 | 87  | 1.13 | 10 | 1.58 | 10 | 6.05# |
| Male                | 146 | 1.34# | 26 | 1.31 | 94  | 1.16 | 11 | 1.22 | 5  | 2.20  |
| **Age at diagnosis of second primary** |     |      |    |      |     |      |    |      |     |      |     |      |
| 0–19 years          | 1   | 5.78  | 0  | 0.00 | 0   | 0.00 | 0  | 0.00 | 4  | 11.51# |
| 20–39 years         | 12  | 2.99# | 3  | 1.86 | 6   | 1.78 | 0  | 0.00 | 4  | 7.47# |
| 40–59 years         | 60  | 1.39# | 18 | 1.38 | 45  | 1.24 | 5  | 1.45 | 3  | 2.02  |
| 60–79 years         | 171 | 1.29# | 23 | 0.98 | 117 | 1.19 | 15 | 1.54 | 3  | 2.31  |
| 80+ years           | 36  | 1.35  | 6  | 1.93 | 13  | 0.66 | 1  | 0.57 | 1  | 3.77  |
| **Site recode ICD-O-3/WHO 2008 of first malignancy** |     |      |    |      |     |      |    |      |     |      |     |      |
| All solid tumors    | 251 | 1.30# | 36 | 0.94 | 148 | 1.01 | 19 | 1.33 | 13 | 3.75# |
| Oral cavity and pharynx | 12 | 2.71# | 2  | 2.13 | 5   | 1.46 | 1  | 2.59 | 0  | 0.00  |
| Digestive system    | 32  | 1.00  | 5  | 0.85 | 23  | 0.94 | 2  | 0.83 | 1  | 2.19  |
| Respiratory system  | 12  | 1.22  | 3  | 1.47 | 12  | 1.59 | 1  | 1.17 | 0  | 0.00  |
| Bones and joints    | 1   | 4.75  | 0  | 0.00 | 0   | 0.00 | 0  | 0.00 | 0  | 0.00  |
| Soft tissue including heart | 2 | 1.99 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 38.49# |
| Skin excluding basal and squamous | 53 | 5.17# | 0 | 0.00 | 11 | 1.42 | 2 | 2.69 | 1 | 3.41 |
| Melanoma of the skin| 51  | 5.39# | 0  | 0.00 | 9   | 1.26 | 2  | 2.90 | 1  | 3.66  |
| Other non-epithelial skin | 2 | 2.55 | 0 | 0.00 | 2 | 3.34 | 0 | 0.00 | 0 | 0.00  |
| Breast              | 47  | 1.12  | 8  | 0.85 | 27  | 0.82 | 6  | 2.23 | 2  | 3.35  |
| Female genital system | 17 | 1.02  | 1  | 0.27 | 11  | 0.84 | 1  | 0.87 | 0  | 0.00  |
| Male genital system | 49  | 0.90  | 12 | 1.24 | 44  | 1.10 | 6  | 1.41 | 3  | 3.10  |
| Prostate            | 46  | 0.86  | 11 | 1.17 | 42  | 1.07 | 6  | 1.45 | 3  | 3.40  |
| Urinary system      | 24  | 1.30  | 4  | 1.20 | 14  | 1.02 | 0  | 0.00 | 0  | 0.00  |
| Brain and other nervous system | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 3 | 33.96# |
| Endocrine system    | 4   | 1.17  | 1  | 1.03 | 2   | 0.72 | 0  | 0.00 | 1  | 5.69  |
| Thyroid             | 4   | 1.22  | 1  | 1.07 | 2   | 0.75 | 0  | 0.00 | 1  | 6.49  |
| All Lymphatic and hematopoietic diseases | 22 | 1.80# | 14 | 5.41# | 29 | 3.08# | 2 | 2.18 | 2 | 4.73 |
| Lymphoma            | 18  | 2.44# | 12 | 7.48# | 22  | 3.87# | 0  | 0.00 | 1  | 4.50  |
| Hodgkin lymphoma    | 0   | 0.00  | 2  | 9.08# | 1   | 1.70 | 0  | 0.00 | 0  | 0.00  |
| Non-Hodgkin lymphoma| 18  | 2.71# | 10 | 7.23# | 21  | 4.12# | 0  | 0.00 | 1  | 6.57  |
| Myeloma             | 0   | 0.00  | 0  | 0.00 | 4   | 4.25# | 0  | 0.00 | 0  | 0.00  |
did not report SPMT in the EOA region after breast cancer [4, 22, 23] and prostate [24].

Age pattern for second malignancies in the EOA is different from that for second malignancies elsewhere, where our results showed 58.9% of the patients developing second malignancies in the EOA are in the age range of 50–69 years at their first presentation. While the previously published relative risk of developing second malignancies was 6-fold higher for survivors of childhood cancer. This may be attributed to the effect of initial therapy, genetic susceptibility, and the age effect [17]. Both males and females showed a significantly higher risk of a second malignancy in the EOA, which is consistent with Youlden et al. [16]. Curtis et al. reported that females had a slightly higher relative risk than males for all subsequent cancers [17].

Regarding the type of first primary tumor, we found that prior NHL was associated with a significant increase in the risk of second malignancies in the lacrimal gland, ciliary body, orbit, and eyelid. NHL is associated with SPMT in different sites. In a large-scale analysis of NHL cases, the EOA region was reported to develop SPMT with a SIR of 1.73. This is in agreement with our results, while the difference in the SIR may be attributed to the combined analysis of the eye and the ocular adnexal regions in their analysis [3]. Similarly, NHL had a pooled RR of 1.43 for SPMT in the EOA region in a meta-analysis, which included 23 studies [5]. However, the combined analysis for the whole region may account for the lower SIR in these studies compared with ours. Nonetheless, the excess risk for SPMT after NHL is well documented and reported [25, 26].

Eyeball malignancies are not far from the orbital ones, sharing similar challenges. Ocular metastasis is well studied, being the most common intraocular malignancy, where near half of these tumors originate in the breast, followed by lung and prostate [6, 20]. SEER central quality control paid attention to differentiate between metastasis and second primaries according to IARC Guidelines. Therefore, the observed patterns in our study are different from the distribution of other common malignancies and their metastasis.

Conjunctiva is another site that possessed a significantly higher risk of SPMT after NHL with no significant influence of gender or age. Eyelid is a known site for primary as well as metastatic tumors. As well, it showed a higher risk for SPMT that was significantly higher for males, females, and all age groups in our analysis. Basal and squamous cell carcinomas were the most prevalent primary eyelid malignancies. Similarly, they were significantly detected as SPMT in the eyelid. Skin melanoma and NHL were reported as primary malignancies for SPMT in the eyelid. As well, they may be the SPMT in the eyelid in contrast to their rare primary occurrence in the eyelid [27–29]. The paucity of the literature of eyelid SPMT hinders comparing our results to explore matching or discrepancy.

**Table 3 (continued)**

| C44.1-Eyelid | C44.5-Lacrimal gland | C72.3-Optic nerve | C80.8-Overlapping lesion of eye and adnexa | O/E | NE | O/E | NE | O/E | NE |
|--------------|----------------------|-------------------|------------------------------------------|-----|----|-----|----|-----|----|
| Leukemia     | 1.10                 | 2.80              | 1.08                                     | 2   | 0.89| 1.91| 2   | 6.26| 2   |
| Lymphocytic leukemia | 0.67 | 3.59              | 1.91                                     | 2   | 0.01| 2.19| 2   | 6.26| 2   |
| Non-lymphocytic leukemia | 0.00 | 0.00              | 0.00                                     | 2   | 0.00| 0.00| 2   | 0.00| 2   |
| Acute non-lymphocytic leukemia | 0.00 | 0.00              | 0.00                                     | 2   | 0.00| 0.00| 2   | 0.00| 2   |
| Myeloid and monocytic leukemia | 0.00 | 0.00              | 0.00                                     | 2   | 0.00| 0.00| 2   | 0.00| 2   |
| Kaposi sarcoma | 0.00 | 0.00              | 0.00                                     | 2   | 0.00| 0.00| 2   | 0.00| 2   |
| Miscellaneous | 5.14#               | 0.00              | 5.14#                                    | 0   | 0.00| 0.00| 0   | 0.00| 0   |

**Table 3**

| | NE | O/E | NE | O/E | NE | O/E |
|---|----|-----|----|-----|----|-----|
| Leukemia | 1.10 | 2.80 | 1.08 | 2 | 0.89 | 1.91 | 2 | 6.26 | 2 |
| Lymphocytic leukemia | 0.67 | 3.59 | 1.91 | 2 | 0.01 | 2.19 | 2 | 6.26 | 2 |
| Non-lymphocytic leukemia | 0.00 | 0.00 | 0.00 | 2 | 0.00 | 0.00 | 2 | 0.00 | 2 |
| Acute non-lymphocytic leukemia | 0.00 | 0.00 | 0.00 | 2 | 0.00 | 0.00 | 2 | 0.00 | 2 |
| Myeloid and monocytic leukemia | 0.00 | 0.00 | 0.00 | 2 | 0.00 | 0.00 | 2 | 0.00 | 2 |
| Kaposi sarcoma | 0.00 | 0.00 | 0.00 | 2 | 0.00 | 0.00 | 2 | 0.00 | 2 |
| Miscellaneous | 5.14# | 0.00 | 5.14# | 0 | 0.00 | 0.00 | 0 | 0.00 | 0 |
Lacrimal gland tumors are common among the white race with an age-adjusted incidence rate of 0.6 per 1,000,000. In the USA, NHL is the most common primary lacrimal gland malignancy. In our study, the lacrimal gland did not show a significantly higher overall risk for SPMT. NHL dominated as the only significant pathological type of SPMT. Nonetheless, the lacrimal gland was not reported among SPMT after NHL elsewhere [3, 5]. Lacrimal gland secretion decreases with radioiodine in thyroid carcinoma therapy, a mechanism that may contribute to the risk of SPMT in the lacrimal gland after radiation for other malignancies [30].

EOA tumors are among the most challenging malignancies. Five-year survival after the exenteration for orbital tumors reached 57% [31]. SPMTs in the EOA are not an exception for this, our study showed a significantly worse survival in the former.

Figure 1 shows different patterns in annual incidence rates of first and second primaries where first primary malignancies showed multiphasic pattern and second primary malignancies showed a steady increase. The potential causes for first primary malignancies were discussed elsewhere [32]. Our paper presents a new pattern in second ocular and its adnexal malignancies that may not be influenced by the same factors. Such point is a potential for future further research for investigating the underlying molecular and genetic differences between the cancers especially in non-Hodgkin’s lymphoma and melanoma.

Our literature review of the most common pathological subtypes and/or sites revealed shared predisposing genes (Supplementary Table 1). We believe that such shared genetic factors may play a role for predicting the incidence of a second malignancy. Moreover, it can guide minimizing the panel used for targeting the second malignancy.

The current study has superior reliability compared with other case studies in terms of the primary sites reported and the histological type of malignancies. However, the retrospective nature of our study carries a potential risk of bias due to the misreporting of the primary malignancy for SPMT or other demographic data. Other limitations are related to the coding of cancer registries, where some anatomical regions are not represented in topographical classifications, e.g., orbital bones and minute orbital structures, e.g., ganglia.

In conclusion, we propose that second ocular and its adnexal primary malignancies are driven by a different underlying mechanism from first primaries. Moreover, a primary malignancy should raise the suspicion for screening either for metastasis or SPMT with any innocent presentation. So, it is recommended to perform a thorough ophthalmic examination with particular attention to the eyelid, the conjunctiva, and the eyeball in the follow-up of cancer cured patients. This is of paramount importance if the first primary malignancy was after the age of 20 years in white race patients. As well, a prior history of any of NHL, EOA malignancy, melanoma, and oropharyngeal malignancies should be thoroughly assessed for potential SPMT in the EOA region.
Acknowledgments The authors would like to thank the NCI SEER program team for their efforts and cooperation during the data extraction phase of the project.

Authors’ contribution ASA participated in designing the concept of the paper, conducted data analyses and had full access to the database, and supervised the whole project scientifically and had final responsibility for the decision to submit for publication. AS conducted all data analyses and had full access to the database. OS participated in designing the concept of the paper and co-supervised the whole project scientifically. All authors have contributed to data interpretation and writing the paper. All authors have revised and agreed to the content of the paper.

Funding Open Access funding provided by Projekt DEAL. Ahmad S. Alfaar was supported by grant 57147166 from The German Academic Exchange Service (DAAD).

Data availability Not applicable.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. SEER data are anonymized and considered non-human subject research. Thus, it is IRB approval and HIPAA is exempted.

Code availability Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hassan WM, Alfaar AS, Bakry MS, Ezzat S (2014) Orbital tumors in USA: difference in survival patterns. Cancer Epidemiol 38:515–522. https://doi.org/10.1016/j.canep.2014.07.001
2. Abdel-Wahab M, Reis IM, Hamilton K (2008) Second primary cancer after radiotherapy for prostate cancer—a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 72:58–68. https://doi.org/10.1016/j.ijrobp.2007.12.043
3. Brennan P, Scéo G, Hemminki K et al (2005) Second primary cancers among 109,000 cases of non-Hodgkin’s lymphoma. Br J Cancer 93:159–166. https://doi.org/10.1038/sj.bjc.6602654
4. Marcheselli R, Marcheselli L, Cortesi L et al (2015) Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer 18:378–385. https://doi.org/10.4048/jbc.2015.18.4.378
5. Pirani M, Marcheselli R, Marcheselli L et al (2011) Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis. Ann Oncol 22:1845–1858. https://doi.org/10.1093/annonc/mdq697
6. Amichetti M, Caffo O, Minatel E et al (2000) Ocular metastases from breast carcinoma: a multicentric retrospective study. Oncol Rep 7:761–765. https://doi.org/10.3892/or.7.4.761
7. Char DH, Miller T, Kroll S (1997) Orbital metastases: diagnosis and course. Br J Ophthalmol 81:386–390. https://doi.org/10.1136/bjo.81.5.386
8. Fahmy P, Heegaard S, Jensen OA, Praise JU (2003) Metastases in the ophthalmic region in Denmark 1969–98. A histopathological study. Acta Ophthalmol Scand 81:47–50
9. Husain A, Blumenschein G, Esmaeili B (2008) Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol 47:276–279. https://doi.org/10.1111/j.1365-4632.2008.03496.x
10. Magliozzi P, Strianese D, Bonavolontà P et al (2015) Orbital metastases in Italy. Int J Ophthalmol 8:1018–1023. https://doi.org/10.3980/j.issn.2222-3959.2015.05.30
11. Valenzuela AA, Archibald CW, Fleming B et al (2009) Orbital metastasis: clinical features, management and outcome. Orbit 28:153–159
12. Woo KI, Harbour JW (2010) Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. Arch Ophthalmol 128:865–870. https://doi.org/10.1001/archophthalmol.2010.126
13. ‘National Cancer Institute, DCCPS SRP (2017) Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975–2016) <Karinna/Rita Population Adjustments> - Linked To County Attributes - Total U.S., 1969–2017. Accessed 8 July 2020
14. Eckardt AM, Rana M, Essig H, Gellrich N-C (2011) Orbital metastases as first sign of metastatic spread in breast cancer: case report and review of the literature. Head Neck Oncol 3:37. https://doi.org/10.1186/1758-3284-3-37
15. Rossi L, Zanella S, Civitelli L, Ranieri E (2014) An unusual orbital metastasis of breast cancer. Breast Dis 34:173–176. https://doi.org/10.3233/BD-140367
16. Youlden DR, Baade PD (2011) The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 11:83. https://doi.org/10.1186/1471-2407-11-83
17. Curtis R, Freedman D, Ron E et al (2006) New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. Bethesda, MD
18. Lains I, Bartosch C, Mondim V et al (2016) Second primary neoplasms in patients with uveal melanoma: a SEER database analysis. Am J Ophthalmol 165:54–64. https://doi.org/10.1016/j.ajo.2016.02.022
19. Abramson DH, Melson MR, Dunkel IJ, Frank CM (2001) Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 108:1868–1876. https://doi.org/10.1016/s0161-4443(01)00713-8
20. Freedman MI, Folk JC (1987) Metastatic tumors to the eye and orbit. Patient survival and clinical characteristics. Arch Ophthalmol 105:1215–1219. https://doi.org/10.1001/archoph.1987.01060090073031
21. Gündalp I, Gündüz K (1995) Metastatic orbital tumors. Jpn J Ophthalmol 39:65–70
22. Marcu LG, Santos A, Bezak E (2014) Risk of second primary cancer after breast cancer treatment. Eur J Cancer Care (Engl) 23: 51–64. https://doi.org/10.1111/ecc.12109

23. Silverman BG, Lipshitz I, Keinan-Boker L (2017) Second primary cancers after primary breast Cancer diagnosis in Israeli women, 1992 to 2006. J Glob Oncol 3:135–142. https://doi.org/10.1200/JGO.2016.003699

24. Joung JY, Lim J, Oh C-M et al (2015) Risk of second primary cancer among prostate cancer patients in Korea: a population-based cohort study. PLoS One 10:e0140693. https://doi.org/10.1371/journal.pone.0140693

25. Morton LM, Curtis RE, Linet MS et al (2010) Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 28:4935–4944. https://doi.org/10.1200/JCO.2010.29.1112

26. Tward JD, Wendland MMM, Shrieve DC et al (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107:108–115. https://doi.org/10.1002/cncr.21971

27. Leventhal HH, Messer RJ (1972) Malignant tumors of the eyelid. Am J Surg 124:522–526. https://doi.org/10.1016/0002-9610(72)90079-7

28. Svendsen FH, Rasmussen PK, Coupland SE et al (2017) Lymphoma of the eyelid - an international multicenter retrospective study. Am J Ophthalmol 177:58–68. https://doi.org/10.1016/j.ajo.2017.02.004

29. Svendsen FH, Heegaard S (2017) Lymphoma of the eyelid. Surv Ophthalmol 62:312–331. https://doi.org/10.1016/j.survophthal.2016.11.009

30. Fard-Esfahani A, Mirschekarpour H, Fallahi B et al (2007) The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med 32:696–699. https://doi.org/10.1097/RLU.0b013e3181244db6

31. Rahman I, Maino A, Cook AE, Leatherbarrow B (2005) Mortality following exenteration for malignant tumours of the orbit. Br J Ophthalmol 89:1445–1448. https://doi.org/10.1136/bjo.2005.072892

32. Hassan WM, Bakry MS, Hassan HM, Alfaar AS (2016) Incidence of orbital, conjunctival and lacrimal gland malignant tumors in USA from Surveillance, Epidemiology and End Results, 1973-2009. Int J Ophthalmol 9:1808–1813. https://doi.org/10.18240/ijo.2016.12.18

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.